Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 189Magnetic Resonance Spectroscopy 150pembrolizumab 147Carboplatin 110Biopsy 106Cyclophosphamide 92Cisplatin 85Paclitaxel 76Bevacizumab 68Gemcitabine 67Nivolumab 59fludarabine 56Fluorouracil 52Radiotherapy 49Capecitabine 49Pemetrexed 45Dexamethasone 45Oxaliplatin 44Rituximab 43Leucovorin 43atezolizumab 42Docetaxel 41venetoclax 39Doxorubicin 39durvalumab 37Temozolomide 32Standard of Care 32Radiation 32Prednisone 32Cetuximab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Paroxetine × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡